Desidustat - Zydus Cadila
Alternative Names: Oxemia; ZYAN-1; ZYAN-1-1001Latest Information Update: 28 Jun 2025
At a glance
- Originator Zydus Cadila
- Developer China Medical System; Zydus Cadila
- Class Acetic acids; Amides; Antianaemics; Cyclopropanes; Quinolines; Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Phase II COVID 2019 infections
- No development reported Chemotherapy-induced anaemia
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Chemotherapy-induced-anaemia in USA (PO, Tablet)
- 14 Oct 2024 Zydus Cadila in collaboration with Indian Council of Medical Research plans a phase IIa proof-of-concept trial for Sickle cell anaemia (PO, Tablet)
- 23 Apr 2024 Preregistration for Anaemia in China (PO) prior to April 2024